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ABSTRACT 
Infections from HIV, Hepatitis B virus constitute a major public health challenge in sub-Saharan Africa, and there 
are evidences to suggest that there is faster progression of HIV in those co-infected with either HBV. The aim of this 
study was to determine the prevalence of HBV infections among HIV-infected patients, and describe the socio-
demographic features and correlates of HIV and HBV co-infected patients at Specialists Hospital, Ekiti, Nigeria. 
One hundred and fifty eight (158) HIV individuals who consented to the study were tested for HBV using Diaspot 
HBsAg kit (Screening test) and Biorex Diagnostic ELISA kit (Confirmatory test) between November 2012 and 
April, 2013. CD4 counts were also analysed with Aldrich Sigma kit and flow cytometery respectively. P value < 
0.05 was considered to be significant. Prevalence rates of Hepatitis B infections among HIV obtained were 5.7%. 
Individuals who were 51 years or younger were the most affected HBV co-infection was more common among 
females than males (3.8%: 1.8%, res, P = 0.0004). Out of 9 patients, 8 patients (88.9%) fell within the age range 30-
49 years which implies the high prevalence of HIV among labour force while 1 patient (11.1%) fell within the range 
of 50-60 years .Mean serum ALT and AST among participants with HIV alone were (42.0, 38.3) International Units 
(IU), but were significantly higher (57.6, 43.7) International Units (IU) for those with HIV/HBV co-infection, P = 
(0.048, 0.032).Mean CD 4 count for HIV/HBV co-infected participants (389 cell/mm 3 ) was significantly higher 
than that for participants with HIV alone (230 cell/mm 3 ), P = 0.024 Conclusion: Co-infection with hepatitis B 
virus is common among HIV-infected patients in our setting and this further reaffirms the need for routine baseline 
screening for this marker, as it is a major consideration in the initiation and choice of highly active antiretroviral 
therapy. Furthermore, those found to be negative should be immunized with HBV vaccine to improve the prognosis 
of their HIV status. 
Keywords: Hepatitis B, Hepatitis C, HIV, Nigeria, Prevalence. 
Introduction 
 
 
There are estimated 34.2 million people living with 
HIV/AIDS worldwide, and sub-Saharan Africa remains 
the region most affected by the global Acquired 
Immunodeficiency Syndrome (AIDS) pandemic [1]. 
 On the other hand Hepatitis B virus (HBV) constitutes 
a major public health challenge in this same region of 
the world with prevalence of >8% of the population.  
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Epidemiologically HIV and HBV have common routes 
of transmission, hence the frequent occurrence of their 
co-infections. 
Additionally, HIV immunosuppression may be 
associated with reactivation of HBV infection in 
persons who have lost detectable HBsAg, or HBeAg, 
or developing AIDS [2] or re-infection in patients who 
have lost protective anti-HBs or are progressing to 
AIDS [3]. Human Immunodeficiency Virus (HIV) is a 
lentivirus that infects cells of the human immune 
system and destroys or impairs their function. Infection 
with this virus results in the progressive deterioration 
of the immune system, leading to 'immune deficiency 
[5].While hepatitis is the inflammation of the liver; it 
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may be caused by exposure to certain chemicals, 
autoimmune diseases, or by bacterial infections but is 
often caused by one of several viruses [6].The hepatitis 
B virus  can be transmitted through  contact with 
infected blood and other body fluids and is transmitted 
from person to person through unprotected sexual 
intercourse with an infected person, sharing infected 
needles, or other sharp agents that break the skin [6]. 
Hepatitis B virus and HIV have been associated with 
reduced survival, increase risk of progress to liver 
disease and hepatotoxicity associated with anti- 
retroviral therapy. Hepatitis B virus and HIV share the 
same routes of transmission; as a consequence, 
infection with HBV is expected in HIV infected 
patients. Hepatitis B virus (HBV) infection is one of 
the most common infections in the world, with 
approximately 2 billion people infected [7] 
HBV exhibits a mutation rate more than 10-fold higher 
than other DNA viruses and more closely resembles 
the replication characteristics of RNA viruses like HIV 
[8]. This leads to a high mutation rate and constant 
production of new viral variants, even in the absence of 
antiviral treatment. The rate at which nucleotide 
substitutions develop varies at different stages of 
infection. The natural evolutionary rate for the HBV 
genome in chronic hepatitis B is approximately 1.4 - 
3.2 x 10-5 substitutions per site per year, which is 
approximately the same as retroviruses (10−5) but 104 
times higher than DNA genomes [9] The high 
mutations lead to complex mixtures of genetic variants, 
also known as “quasispecies,” which result from this 
high-level, low-fidelity replication, and circulate in 
various reservoirs specific to each virus.   
Under the selective pressure of antiviral therapy that 
does not profoundly suppress viral replication; drug-
resistant strains are selected for as the dominant 
species, with the potential loss of virological 
suppression.  Both viruses have rapid development of 
drug-resistant viral variants during suboptimal therapy, 
and it’s because of both the high rate of replication and 
turnover of virus (HIV produces ~ 10 billion new viral 
particles per day while HSV produces at least 10 times 
that number in each infected individual) [10] and the 
high error rate of the HIV reverse transcriptase and 
HBV polymerase enzymes.  As a result of similar 
polymerase enzyme, HBV and HIV share a number of 
antiviral drugs, and hence the development of similar 
antiviral resistance patterns during antiviral therapy. 
There is overwhelming evidence that HIV co-infection 
impacts very negatively in the modification of the 
natural history of HBV infections [4]. However, there 
has not been any convincing evidence that showed 
HBV to impact the course of HIV disease [11]. Other 
studies have also suggested HBV protein (HBx) being 
responsible in super inducing ongoing HIV replication 
and HIV long-term repeated transcription by 
synergizing with tat-protein and T-cell activation 
signals. These findings indicate that HBx could 
promote faster progression to AIDS in HBV/HIV-co-
infected individuals.  Studies from the pre-HAART era 
did not demonstrate a significant impact of HBV 
carriage on HIV disease progression [12]. While HBV 
does not seem to influence HIV disease progression, 
there is overwhelming evidence that HIV impacts very 
negatively on the HBV natural infections. This 
includes: (i) Increase in progression to HBV chronic 
carriage; (ii) Reduced persistence of anti-HBs and anti-
HBc; (iii) Increased HBV infectivity (iv) Increased 
transmission of HBV; and (v) Impact on liver disease 
and (vi)occult hepatitis B infections diagnosis [4].  
Studies have shown that HIV/AIDS individuals co-
infected with HBV are less likely to clear acute HBV 
infection spontaneously, resulting to chronic infection.  
This study therefore aims to determine the prevalence 
and demographics characteristics of HBV infection 
among HIV infected individuals in Ikole Ekiti, Nigeria.  
 
Materials and methods  
 
The study was conducted in IHVN Clinic, Specialist 
Clinic, Ikole Ekiti, and Medical Microbiology and 
Parasitology Laboratory, Laboratory complex, Osogbo, 
Nigeria. Ethical approval was obtained from Permanent 
Secretary, Ministry of Health, Ekiti State.  A total of 
158 consecutive patients with HIV infection seen at the 
Specialist Hospital, Ikole Ekiti, Nigeria were selected 
for the study. Information was obtained with the aid of 
an interviewer-administered questionnaire. Status of 
serological markers for HIV and HBV (HBsAg) were 
determined using Enzyme-linked Immunosorbent 
Assay (ELISA).HIV screening was done using the 
national algorithm; i.e., using 
DETERMINE TM (manufactured by ABBOTT CO 
LTD, MINATO-KU, JAPAN) and STAT 
PAK TM (manufactured by CHEMBIO DIAGNOSTIC 
SYSTEMS INC, USA) techniques and a third test 
GENIE II test served as a tie breaker if there were 
discordant results with the first two tests. HBsAg test 
was done using First Response HBsAg Card Test, 
manufactured by PMC Medical (India) Pvt. Ltd. 
Kachigam Daman (UT) 396215, India. CD 4 Count 
Estimations were done using Cyflow SL-Green, 
manufactured by Patex, Germany. Study centre is 
Medical Microbiology and Parasitology Laboratory, 
Laboratory complex, LAUTECH, Osogbo, Nigeria. 
Data were analysed using statistical package within the 
Microsoft Excel and SPSS software to determine the 
effect of sex, age, CD4 count and Liver enzymes on the 
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data obtained. P < 0.05 was considered to be 
significant. 
 
Results 
 
Among the study subjects, there were fourty males 
(25.3%) and One hundred and eighteen females 
(74.7%) as shown in table 4.1. These patients aged 
between 3-82 years with mean age was 35 years. One 
hundred and twenty four (83.2%) patients fell within 
the age range 30-49 which implies the high prevalence 
of HIV among adult. Mean and median CD4 T 
lymphocyte count of the study participants were 
210/mm3 and 142/mm3 respectively.  
HBsAg is the main serological marker for diagnosis of 
HBV infection as it indicates either an active or chronic 
state, this study detected nine patients were positive for 
HBsAg and later confirmed with ELISA and therefore 
the prevalence of HBV infection was 5.7%. Among the 
study subjects, there were 3 males (1.9%) and 6 
females (3.8%). These patients aged between 28-54 
years, mean age was 35.5 years and median age was 36 
years. Out of 9 patients, 8 patients (88.9%) fell within 
the age range 30-49 years which implies the high 
prevalence of HIV among adult while 1 patient 
(11.1%) fell within the range of 50-60 years.  
The entire patients had normal ALT and AST except 
one. Five (3.2%), 3 (1.9%) and 1 (0.6%) fell within the 
CD4 of greater than 500, 200-499 and < 200 cells/mm3 
respectively as shown in table 1. Table 4.1also showed 
the distribution of the human immunodeficiency virus 
(HIV) infected in study participant as per Centers for 
Diseases Control (CDC) classification for HIV infected 
adults and adolescents with the mean CD4 lymphocyte 
count in each category. Fifty four patients (36.2%) had 
CD4 count of more than 500 cell/mm3, 68 patients 
(45.6%) had CD4 count ranging from 7- 56 cells/mm3 
and 27 patients (18.2%) had CD4 count of less than 
200 cells/mm3. 
  
 
 
 
 
                                                                                                      
Table 4.1: The baseline characteristics of HBV negative and positive patients 
Parameters   HBV -Ve(149) HBV +ve (9)   All patient(158)  
Sex     
Male  37(24.8%) 3(33.3%) 40  
Female 112(75.2%) 6(66.7%) 118  
Age      
<20 8(5.4% ) 0 8  
20-29 1(0.67 %) 0 1  
30-49 124(83.3 %) 8(88.9%) 132  
>50 16(10.7 %) 1(11.1 %) 0  
Mean  35yrs 36yrs 35.5yrs  
Range 3-82yrs 28-54yrs 3-82yrs  
CD4     
>500 54((36.2 %) 5(55.6 %) 59  
200-499 68(45.6%) 3(33.3%) 71  
<200 27(18.2 %) 1(11.1 %) 28  
Table 4.2: Classified alaline transaminase (ALT) and aspartate transaminase (AST) of the patients into three 
(3) groups. 143 (95.6%) had normal ALT and 6 (4.4%) had raised ALT while 130 (87.5%) showed normal 
AST and 19 (12.8%) showed higher AST  
Parameters  HBV –Ve (149) HBV +Ve (9) All Patients  
ALT(IU/L)     
<7    3(2.01%)         1(11.1%)           4  
7-56   140(94.0%)         8(88.9%)          148  
>56   5(4.02%)         1           6  
AST(IU/L)     
1-4    0         0           0  
5-40  130(87.25%)         9(100%)          148  
>40   19        0           19  
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The distribution of the study participants according to 
the 1993 Revised Classification System for HIV 
Infection and Expanded Surveillance Case Definition 
for AIDS among Adolescents and Adults were as 
shown in Table 4 3. Sixteen (10.7%) of patients were 
of age greater than 50 years, 8 (5.4%) of teenager and 
no children was affected. All 158 serum samples was 
confirmed HIV positive. 
Table 4.3: The distribution of the human immunodeficiency virus (HIV) infected in study participant as per 
Centers for Diseases Control (CDC) classification for HIV infected adults 
Category CD4 No of Patients Mean CD4 count 
1 T cells >500cells/mm3 59 118.36 
2 T cell 200-499cells/mm3 71 32.24 
3 T cells <200 cells/mm3 28             32.11 
 
 
Mean serum ALT and AST level among participants 
with HIV alone were (42.0, 38.2) International Units 
(IU), and this was significantly higher (57.6, 43.0) 
International Units (IU) for those with HIV/HBV co-
infection, P = (0.048, 0.032).The mean CD 4 count for 
HIV/HBV co-infected participants (259.7 cell/mm3) 
was significantly higher than that for participants with 
HIV alone (230.0 cell/mm3), P = 0.024.  
 
Table 4.4: Compares the liver enzymes and CD4 count of the HIV with HIV- HBV coinfected patients 
Characteristic (mean) HIV only, n=149 HIV/ HBV, n=9 P value 
Age (years) 34 39 0.34 
ALT (IU/L) 220 389 0.024 
AST (IU/L) 42.0 57.6 0.048 
CD4 (cell/mm3) 38.2 43 0.032 
HIV: Human immunodeficiency virus, HBV: Hepatitis B virus, ALT: Alanine transaminase, AST: Aspartate 
Transaminase 
 
Discussion 
 
From this study, the prevalence of HBV co-infections 
among HIV infected individuals in Ikole Ekiti, Ekiti 
State; South-Western, Nigeria is 5.7%. The observed 
prevalence rate of 5.7%  in HIV infected individuals 
attending the IHVN clinic may be due  to rural location 
of the site of the study but it is however an indication 
of the rising prevalence of HBV infection in this 
environment. This 5.7% value reported in this study is 
lower than the 9.7% by Ejele et al  in the Niger Delta 
area of Nigeria, 11.9% reported by Otegbayo et al. 
(2008) in Ibadan, 16.7% reported by Idoko et al in Jos 
and 25.0% by Uneke et al. (2005) among HIV-infected 
in Nigeria.  
The differences in prevalence in these studies could be 
attributed to differences in patient selection. Gender-
specific prevalence showed that females had higher 
seropositivity for HIV- HBV co-infections (3.8%) than 
their male counterparts with (1.9%) prevalence. This 
observation however, disagrees with the report by 
Mehmet et al. (2005) in which males had higher 
prevalence rate than females in both rural and urban 
areas with observation that male sex was an important 
risk factor for HBV positivity. The statistically 
significant difference in HIV- HBV co-infections 
between males and females in the present study 
suggests that they were not equally exposed to HBV-
HIV in corroboration to earlier findings [13]. 
A prevalence of 5.7% was found among HIV patients 
attending Specialist hospital, Ikole Ekiti, Nigeria were 
seropositive for hepatitis B virus which may probably 
be a pointer to the fact that HBV infection is the major 
threat to the HIV infected patients as a result increase 
hepatotoxicity after initiation of antiretroviral therapy. 
Therefore, HIV infected patients should be screened 
for as well as vaccinated against HBV infection prior to 
the initiation of antiretroviral therapy. There should 
also be more awareness and campaign on HBV 
infection prevention. 
Baseline ALT was significantly higher among 
HIV/HBV co-infected participants compared to those 
with HIV alone and this is in agreement with the 
findings of Zhou et al., 2007 [14]. There was an 
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elevation of liver enzymes among all the patient 
groups. The mean level was highest for those co-
infected with hepatitis B. This finding is corroborated 
by a study in Lagos [15]. In that study, liver enzymes 
were significantly higher in HIV patients than in 
controls, as well as higher in HIV patients who were 
also positive for hepatitis B surface antigen compared 
to those not co-infected. This finding highlighted some 
challenges being encountered in treating patients who 
were co-infected, especially regarding the choice of 
HAART regimen, how to prevent further hepatic 
damage, and when to initiate HAART, especially in 
resource-limited settings with limited ARV options 
[15].   
A statistically significant relationship was found 
between the mean CD 4 count and HBsAg serological 
status of the participants. Individuals with HIV/HBV 
co-infection had the highest mean value of CD 4 count 
(P = 0.024) when compared with participants with HIV 
alone. Previous investigators reported variable 
findings, with some corroborating findings similar to 
this study. However, the implication of this finding 
may relate to HAART-associated hepatotoxicity which 
is commonly seen in patients with relatively higher 
baseline CD 4count, for instance HAART-naïve women 
with baseline CD 4 count > 250/mm 3 and HAART-
naïve men with CD 4 count > 400/mm 3 are at increased 
risk of hepatotoxicity when started on Nevirapine-
based HAART. The mechanism of HAART-related 
hepatotoxicity in patients with HIV/HBV co-infection 
is mainly by immune reconstitution and some authors 
have identified an increase in CD 4 count of 
>50/mm 3after initiating HAART as an independent 
risk factor for hepatotoxicity[16]. 
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